Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan Medoxomil/Amlodipine vs Amlodipine in Chinese Patients With Mild to Moderate Essential Hypertension
jRCT2080221541Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Olmesartan medoxomil/amlodipine 20/5 mg with Amlodipine 5 mg (2 arms).
02
Drugs
olmesartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080221541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221541.